RETO vs MEDS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 08, 2026

RETO

26.0
AI Score
VS
MEDS Wins

MEDS

40.1
AI Score

Investment Advisor Scores

RETO

26score
Recommendation
AVOID NEW MONEY

MEDS

40score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric RETO MEDS Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 118.9% 0.0% RETO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 26.0/100 40.1/100 MEDS
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD MEDS

Frequently Asked Questions

Based on our detailed analysis, MEDS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.